MX2022013288A - Composiciones y metodos para el tratamiento de proteinopatias por la proteina 43 de union a acido desoxirribonucleico (adn) de respuesta transactiva (tdp-43). - Google Patents
Composiciones y metodos para el tratamiento de proteinopatias por la proteina 43 de union a acido desoxirribonucleico (adn) de respuesta transactiva (tdp-43).Info
- Publication number
- MX2022013288A MX2022013288A MX2022013288A MX2022013288A MX2022013288A MX 2022013288 A MX2022013288 A MX 2022013288A MX 2022013288 A MX2022013288 A MX 2022013288A MX 2022013288 A MX2022013288 A MX 2022013288A MX 2022013288 A MX2022013288 A MX 2022013288A
- Authority
- MX
- Mexico
- Prior art keywords
- tdp
- proteinopathies
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016707P | 2020-04-28 | 2020-04-28 | |
| US202063035437P | 2020-06-05 | 2020-06-05 | |
| PCT/US2021/029289 WO2021222168A2 (en) | 2020-04-28 | 2021-04-27 | Compositions and methods for the treatment of tdp-43 proteinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013288A true MX2022013288A (es) | 2023-02-22 |
Family
ID=75905076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013288A MX2022013288A (es) | 2020-04-28 | 2021-04-27 | Composiciones y metodos para el tratamiento de proteinopatias por la proteina 43 de union a acido desoxirribonucleico (adn) de respuesta transactiva (tdp-43). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240327477A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4143215A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7894321B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230025659A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115836129B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021265088A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021604A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013288A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202206446A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021222168A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021367952A1 (en) * | 2020-10-26 | 2023-06-08 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
| US20250205305A1 (en) * | 2022-01-27 | 2025-06-26 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and compositions for rescuing protein misfolding |
| WO2023185017A1 (zh) * | 2022-03-30 | 2023-10-05 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 经修饰的rnf112或包含其的外泌体递送系统 |
| CN114874332B (zh) * | 2022-03-30 | 2023-01-10 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 经修饰的rnf112作为治疗als药物的应用 |
| CN122070299A (zh) * | 2023-09-15 | 2026-05-19 | 普罗塞纳生物科学有限公司 | 细胞穿透剂及其用途 |
| WO2025264861A1 (en) * | 2024-06-18 | 2025-12-26 | Yale University | Compositions of bi-functional alpha helical peptides and methods thereof for treating tdp-43 proteinopathies |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| WO2010111587A1 (en) * | 2009-03-26 | 2010-09-30 | Trustees Of The University Of Pennsylvania | Modulators of tdp-43 mediated toxicity |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| CA2853412C (en) | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| WO2014038884A1 (ko) * | 2012-09-07 | 2014-03-13 | 주식회사 마크로젠 | 융합 단백질 및 이를 포함하는 암 진단용 조성물 |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2929045B1 (en) * | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
| US20160220649A1 (en) * | 2013-09-13 | 2016-08-04 | Fundación Pública Andaluza Progreso Y Salud | Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases |
| WO2016053610A1 (en) | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US10720797B2 (en) | 2017-05-26 | 2020-07-21 | California Institute Of Technology | Method and apparatus for dynamic RF lens focusing and tracking of wireless power recovery unit |
| US11466077B2 (en) | 2018-01-05 | 2022-10-11 | Ac Immune Sa | Misfolded TDP-43 binding molecules |
| JP7320282B2 (ja) | 2018-03-16 | 2023-08-03 | 国立大学法人滋賀医科大学 | 異常tdp-43を分解除去する抗体断片 |
-
2021
- 2021-04-27 JP JP2022565544A patent/JP7894321B2/ja active Active
- 2021-04-27 CN CN202180045995.1A patent/CN115836129B/zh active Active
- 2021-04-27 WO PCT/US2021/029289 patent/WO2021222168A2/en not_active Ceased
- 2021-04-27 US US17/997,142 patent/US20240327477A1/en active Pending
- 2021-04-27 CN CN202610632651.5A patent/CN122444887A/zh active Pending
- 2021-04-27 AU AU2021265088A patent/AU2021265088A1/en active Pending
- 2021-04-27 EP EP21725359.0A patent/EP4143215A2/en active Pending
- 2021-04-27 KR KR1020227041465A patent/KR20230025659A/ko active Pending
- 2021-04-27 MX MX2022013288A patent/MX2022013288A/es unknown
- 2021-04-27 BR BR112022021604A patent/BR112022021604A2/pt unknown
- 2021-04-28 TW TW110115416A patent/TW202206446A/zh unknown
-
2026
- 2026-04-16 JP JP2026067788A patent/JP2026123053A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230025659A (ko) | 2023-02-22 |
| JP2023524414A (ja) | 2023-06-12 |
| JP2026123053A (ja) | 2026-07-29 |
| TW202206446A (zh) | 2022-02-16 |
| AU2021265088A1 (en) | 2022-11-03 |
| EP4143215A2 (en) | 2023-03-08 |
| CN122444887A (zh) | 2026-07-24 |
| CN115836129B (zh) | 2026-05-26 |
| WO2021222168A3 (en) | 2021-12-30 |
| BR112022021604A2 (pt) | 2022-12-06 |
| WO2021222168A2 (en) | 2021-11-04 |
| US20240327477A1 (en) | 2024-10-03 |
| JP7894321B2 (ja) | 2026-07-23 |
| CN115836129A (zh) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021222168A3 (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| MX2022012525A (es) | Composiciones y metodos para el tratamiento de trastornos de agregacion de proteinas. | |
| MX2021012867A (es) | Terapéutica de anticuerpos postraduccionalmente modificados completamente humanos. | |
| AU2018274216A1 (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| MX2020010466A (es) | Vectores de virus que evitan anticuerpos. | |
| WO2025010377A3 (en) | Methods of using anti-sp17 immunotherapeutics | |
| MX2021010840A (es) | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| BR0207325A (pt) | Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1 | |
| PH12021550789A1 (en) | Disulfide bond stabilized polypeptide compositions and methods of use | |
| WO2020163743A8 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
| MXPA05007821A (es) | Terapia de combinacion para tratar deficiencias de proteinas. | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| MX2025009545A (es) | Metodos y composiciones para la administracion de sistemas de vector dual otoferlin | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| MX2022014506A (es) | Cisteina proteasa. | |
| ZA202110285B (en) | Antibodies and methods of use | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MX2023006419A (es) | Compuestos polipéptidos modificados con lactama. | |
| MX2022013638A (es) | Inmunoterapia con citocina. | |
| WO2024030856A3 (en) | Immunomodulatory proteins and related methods | |
| ZA202203360B (en) | Peptide amide composition and preparation method therefor | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| MX2025012846A (es) | Anticuerpo biespecifico dirigido al receptor acoplado a proteina g | |
| MX2022001561A (es) | Ensayos de potencia para la produccion de vectores virales. |